Year: 2020
Language: English
Author(s): World Federation of Hemophilia
Despite significant paradigm shifts in the medical management of hemophilia A with inhibitors and the expanding use of novel non-factor therapies, FVIII-based immune tolerance induction (ITI) is still the only effective means to inhibitor eradication. With the recently introduced Atlanta protocol, emicizumab prophylaxis is given in combination with 50-100 IU/kg FVIII three times a week.
In this session from the WFH 2020 Virtual Summit, Alok Srivastava, Midori Shima, Gallia Levy & Steven Pipe explore the impact of emicizumab prophylaxis for non-inhibitor patients and examine the current status of clinical studies regarding emicizumab prophylaxis.
The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.
In these sessions from the WFH 2022 World Congress, listen to Kate Khair, Luke Pembroke, Louis Marlow, Andrew Selvaggi, Robert
This patient handbook contains basic information about gene therapy for hemophilia. The WFH does not engage in the practice of
In these sessions from the WFH 2022 World Congress, David Lillicrap, Len Valentino, Sophie Susen, Mrinal Gounder, Rebecca Kruse-Jarres, Christine
For people considering taking gene therapy, it is extremely important to learn as much as possible about if you are
This document is an introductory guide for people with hemophilia who wish to join the World Federation of Hemophilia (WFH)
The World Federation of Hemophilia (WFH) Gene Therapy Registry (GTR) welcomes the participation of all Hemophilia Treatment Centres (HTCs) involved